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Background: Primary breast lymphoma (PBL) of low-grade histology is a rare disease. This multicentric retrospective
study was carried out to determine clinical features, prognosis and relapse.
Patients and methods: Patients with histologically proven, previously untreated follicular or marginal-zone PBL
(MZL PBL) diagnosed from 1980 to 2003 were included in the study. Major end points were progression-free survival
(PFS), overall survival (OS) and potential prognostic factors.
Results: We collected data on 60 cases of PBL [36 follicular and 24 marginal-zone lymphoma (MZL)]. Stage was IE or
IIE in 57 patients and IVE in three patients due to bilateral breast involvement. Surgery, chemotherapy and radiotherapy
(RT), alone or in combination, were used as first-line treatments in 67%, 42% and 52% of patients, respectively. Overall
response rate was 98%, with a 93% complete response rate. Five-year PFS were 56% for MZL and 49% for follicular
PBL (P = 0.62). Relapses were mostly in distant sites (18 of 23 cases); no patients relapsed within RT fields.
Conclusions: Our data showed an indolent behaviour of MZL PBL, comparable to other primary extranodal MZL.
Conversely, patients with follicular PBL had inferior PFS and OS when compared with limited-stage nodal follicular
non-Hodgkin’s lymphomas, suggesting an adverse prognostic role of primary breast localisation in this histological
subgroup.
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introduction
Primary breast lymphoma (PBL) is a clinicopathological entity
that represents 1% of all non-Hodgkin’s lymphomas (NHL) [1]
and <0.5% of all breast malignancies [2]. PBL typically affects
an elderly population, but may rarely occur in younger women,
at times associated with pregnancy or lactation; men are very
rarely affected. The large majority of cases of PBL are
represented by diffuse large B-cell lymphoma (DLBCL), with
the remainder comprising follicular lymphoma and marginal-
zone lymphoma (MZL) subtypes [3]. Primary breast
localisation represents a small proportion of extranodal
lymphomas (<5%) in both follicular lymphoma and MZL
subgroups [4]. Although it has been hypothesised that DLBCL
PBL could originate from germinal centre-related B-cells [5],
there is even less known about the pathogenesis of histologically
‘low-grade’ PBL. Surgery, radiotherapy (RT), chemotherapy
(CT) and more recently immunotherapy have been reported as
treatment modalities for PBL either as monotherapy or in
combination. Due to the small number of publications
investigating PBL, there is limited information about this
disease. Moreover, almost all papers are focused on DLBCL,
thus information regarding follicular lymphoma and MZL
subtypes are scarce [6–13]. A pathophysiologic role of chronic
infections has been identified in some extranodal NHL such
as gastric (Helicobacter pylori), ocular adnexal (Clamydia psittaci)
and skin (Borrelia burgdorferi) MZL [14], but such correlations
have not been reported in the literature regarding PBL.
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The International Extranodal Lymphoma Study Group
(IELSG) has conducted a large multicentre retrospective study
of PBL of all histological subtypes in order to review its clinical
characteristics, natural history and prognosis. We present here
the results of the analysis of patients with histologically proven
diagnosis of follicular or MZL PBL.
materials and methods
trial overview and data collection
Data on all cases of PBL diagnosed at each participating institute from
January 1980 to December 2003 were retrospectively collected. Inclusion
criteria for the study were as follows: histologically proven NHL with
primary localisation of one or both breasts, with or without regional lymph
node involvement. Patients with disseminated lymphoma with breast
involvement or breast presentation of recurrent/progressive lymphoma
were excluded. All histological subtypes were eligible. Patients were staged
according to the Ann Arbor classification [15]; the staging of extranodal
NHL involving bilateral paired organs remains contentious, but for this
study patients with bilateral breast disease were considered stage IV.
Protocol and case report forms (CRFs) were approved by the local
institutional review boards or ethics committees of each participating
institution. CRFs were designed to collect data on patient and tumour
characteristics, diagnostic test results, potential prognostic factors,
treatment approaches, response and survival. We also evaluated the
International Prognostic Index (IPI) in all patients [16] and the Follicular
Lymphoma International Prognostic Index (FLIPI) in patients with
follicular PBL [17]. Data for each patient were collected by local
investigators and CRFs were then sent to IELSG headquarters and
analysed centrally.
definition of study outcomes
Tumour response was assessed after the completion of planned treatment
according to the published response criteria [18]. Progression-free survival
(PFS) was calculated as the interval between start of treatment and
progression of disease, death or last known follow-up; overall survival (OS)
was defined as the period between the start of treatment and death from any
cause or last known follow-up; cause-specific survival (CSS) was defined as
the period between the start of treatment and death from disease or
treatment complications.
pathology review
Various histological classifications were in use throughout the study period,
and patients classified according to Kiel, Working Formulation, Revised
European-American Lymphoma or World Health Organisation (WHO)
were all eligible. All cases were locally reviewed, and this report is limited to
the 60 patients with their histology reclassified as either follicular
lymphoma or MZL according to WHO criteria [19].
statistical analysis
Baseline characteristics were summarised as a table of frequencies for
categorical variables and as mean and standard deviation, median and range
for continuous variables. The distribution of these characteristics among
patients with histologically different lymphomas (follicular lymphoma
versus MZL) was compared by the Pearson’s chi-square test for categorical
variables and either t-test or Mann–Whitney–Wilcoxon test (depending on
whether the variable was normally distributed or not) for continuous
variables. Unadjusted time-to-event data distributions (PFS and OS) were
estimated by the Kaplan–Meier method [20]; the comparison between
histologically different lymphomas was carried out by the log-rank test [21].
The univariate Cox models [22] were used to detect and quantify
prognostic factors with potentially different roles between the histological
subtypes. Due to the small number of events within the subpopulations
delineated by the subtypes, a multivariate analysis was not statistically valid.
The analyses were carried out using SAS statistical software (SAS Institute,
Cary, NC).
results
patients
This IELSG study enrolled a total of 278 patients with PBL: 204
of them had DLBCL (73%) and were separately analysed and
have been previously reported [23]. A total of 60 patients with
PBL, 36 with follicular lymphoma and 24 with MZL were
considered and analysed further for this report (Table 1).
Fifty-nine patients were female and only one was male. The
median age was 65 years (range 32–92), 51 patients were
postmenopausal (85%) and 36 patients aged ‡60 years (60%).
No patient was pregnant or lactating at diagnosis. Eastern
Cooperative Oncology Group performance status at diagnosis
was zero to one in 51 patients (85%). Only two patients (3%)
Table 1. Patients’ characteristics
MZL PBL
(N = 24)
Follicular PBL
(N = 36)
All PBL
(N = 60)
Pa
Male/female –/24 1/35 1/59 0.41
Median age, years
(range)
68 (47–92) 62 (32–88) 65 (32–92) 0.16
>60 years 71% 53% 58%
Ann Arbor stage, n (%)
IE 17 (71) 26 (72) 43 (72) 0.95
IIE 6 (25) 8 (22) 14 (23)
IV 1 (4) 2 (6) 3 (5)
B-symptoms, n (%) – 2 (6) 2 (3) 0.24
Primary localisation,
n (%)
Left breast 13 (54) 19 (53) 32 (53) 0.97
Right breast 10 (42) 15 (42) 25 (42)
Bilateral involvement 1 (4) 2 (5) 3 (5)
Lesion dimensions, cm
(median, range)
Left breast 2.9 (1.3–6) 2.4 (0.7–6) 2.5 (0.7–6) 0.9b
Right breast 2.75 (0.8–20) 2 (0.8–9) 2.1 (0.8–20) 0.8b
ECOG, n (%)
0–1 21 (95) 30 (94) 51 (94) 0.91
2 1 (5) 1 (3) 2 (4)
3 – 1 (3) 1 (2)
NA 2 4 6
IPI, n (%)
Low (0–1) 14 (88) 18 (90) 32 (89) 0.67
Low–intermediate (2) 2 (12) 2 (10) 4 (11)
NA 8 16 24
aPearson’s chi-square test.
bWilcoxon’s test.
MZL PBL, marginal-zone PBL; PBL, primary breast lymphoma; ECOG,
Eastern Cooperative Oncology Group; IPI, International Prognostic Index;
NA, not available.
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presented with B-symptoms. Forty-three patients were in stage
IE (72%), 14 patients (23%) were in stage IIE, 11 due to axillary
and three due to supraclavicular nodal involvement, and three
patients were in stage IVE (5%) due to bilateral breast disease.
IPI was evaluated in 36 patients, and it was low (0–1) in 32
patients (89%). FLIPI score was evaluated in 27 of 36 patients
with follicular lymphoma: 24 presented with a low score and
three an intermediate score. There were no statistically
significant differences between baseline characteristics in
patients with MZL and follicular PBL.
diagnosis
Both invasive and noninvasive procedures were carried out as
a part of the diagnostic work-up of the patients (Table 2). Forty-
six patients underwent a noninvasive diagnostic procedure, such
as mammography and/or ultrasound, which confirmed the
presence of pathological lesion in 43 patients (93%). An invasive
procedure was carried out in all 60 patients, aimed at obtaining
a histological diagnosis. Thirty-six patients underwent a fine-
needle aspiration (FNA) for cytology, which was positive in 35
(97%). A surgical biopsy was carried out in 59 patients, and it was
diagnostic in 53 (90%). Overall, FNA and/or surgical biopsy led
to a histological diagnosis in 57 of 60 patients (95%). The
remaining three patients required more invasive diagnostic
surgery: mastectomy and lymph nodal dissection in one patient
and lumpectomy in the other two patients.
treatment
As patients were identified retrospectively from various institutions,
there was no uniform treatment policy, and management was
determined by the individual managing clinicians. RT, CT and
surgery were used alone or in combination (Table 3).
Forty patients (67%) were managed with initial surgery:
a breast-conserving resection was carried out in 31 patients; the
remaining nine underwent a mastectomy. Surgery was used
alone in 11 patients, while the other 29 patients received an
additional treatment modality: six with CT, 15 with RT and
eight patients received both CT and RT. Twenty patients (34%)
did not undergo a surgical procedure: seven of them received
CT alone, nine patients underwent RT alone and four patients
received both CT and RT. Overall, CT was administered in 25
patients with different schedules. Fifteen patients received an
anthracycline- or anthracenedione-based regimen, such as
combination chemotherapy with cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP) or
cyclophosphamide, mitoxantrone, vincristine, prednisone, the
others alkylating agent-based CT (e.g. chlorambucil or
cyclophosphamide, vincristine, prednisone). No patients
received immunotherapy with rituximab or intrathecal
prophylaxis.
RT was administered to breast fields in 36 patients (dose
range 25–50 Gy, median 38 Gy) and nodal fields (axilla and
supraclavicular) were irradiated in 18 patients (dose range 30–
46 Gy, median 36 Gy). While RT was used alone in nine
patients (15%), it was used in association with other therapies
in 27 cases (45%).
Local treatments (e.g. surgery and/or RT) were similarly
distributed between MZL and follicular PBL, as well as the
extent of surgery (i.e. mastectomy). Conversely, systemic CT
was administered in 19 of 36 patients (53%) with follicular PBL
and in 6 of 24 (25%) with MZL PBL (P = 0.03).
response and survival
Considering all first-line treatment combinations, the overall
response rate (ORR) was 98% (100% for MZL and 97% for
follicular PBL): 56 patients (93%) obtained a complete
remission (CR) and three patients (5%) a partial response.
Only one patient with a follicular PBL did not respond to
treatment and had initially stable disease; after 8 years he died
from progressive lymphoma.
Table 2. Diagnostic modalities
MZL PBL (N = 24) Follicular PBL (N = 36) All PBL (N = 60)
Noninvasive diagnostics
Done 20 (20 positive; 100%) 26 (23 positive; 88%) 46 (43 positive; 93%)
Not done 4 10 14
Mammography
Done 20 (19 positive; 95%) 24 (21 positive; 88%) 44 (40 positive; 91%)
Not done 4 12 16
Ultrasound
Done 9 (9 positive; 100%) 15 (13 positive; 87%) 24 (22 positive; 92%)
Not done 15 21 36
Invasive procedure
Done 24 (24 positive; 100%) 36 (33 positive; 92%) 60 (57 positive; 95%)
Not done 0 0 0
Fine-needle aspiration
Done 24 (24 positive; 100%) 12 (11 positive; 92%) 36 (35 positive; 97%)
Not done 0 24 24
Surgical biopsy
Done 24 (22 positive; 92%) 35 (31 positive; 89%) 59 (53 positive; 90%)
Not done 0 1 1
MZL PBL, marginal-zone PBL; PBL, primary breast lymphoma.
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Fourteen patients with follicular PBL (39%) relapsed after
a median interval of 26 months (range 1.2–85 months). Nine
patients with a MZL PBL (37%) relapsed after a median
interval of 12 months (range 4–102 months). No patients who
received RT in first-line treatment (eight with follicular and
eight with MZL PBL) relapsed in the irradiated fields. Of the 23
relapses, three were locoregional, while the remaining were in
contralateral breast (two patients) and in distant sites (18
patients). Considering the three local relapses, two of them had
been treated with systemic CT, whereas the third patients
received combined surgery and chemoradiotherapy: this patient
relapsed outside the irradiated field (ipsilateral axillary nodes).
Relapse rate was also evaluated in order to investigate the role
of an additional treatment (CT and/or RT) after surgery; results
are reported in Table 4.
PFS for MZL and follicular PBL was 72% and 63% at 3 years,
56% and 49% at 5 years and 34% and 28% at 10 years,
respectively (log-rank test: P = 0.55). The median PFS was 7.3
years in MZL and 3.9 years in follicular PBL (Figure 1). No
difference in terms of PFS was detected between the patients
who received a CHOP-like and those treated with alkylating
agent-based CT.
After a median follow-up time of 44 months (range 5–156
months), 17 patients died; 14 with follicular lymphoma and
three with MZL. OS for MZL and follicular PBL was 100% and
75% at 3 years, 92% and 64% at 5 years and 64% and 47% at
10 years, respectively (log-rank test: P = 0.04). The median OS
was 8.1 years in follicular PBL and was not reached in MZL PBL
(Figure 2). Univariate analyses of potential prognostic factors
for PFS and OS were carried out, and the results are
summarised in Table 5. Only impaired PS was shown to have
an impact on OS in follicular PBL, but the analysis was greatly
limited by the small sample size.
Nine patients died from disease: eight of them (89%) had
follicular lymphomas. The CSS for MZL and follicular PBL was
100% and 84% at 3 years, 100% and 79% at 5 years and 80%
and 66% at 10 years, respectively (log-rank test: P = 0.05;
Figure 3).
Three patients developed a second malignancy, but only
a case of acute myeloid leukaemia developing 27 months after
CHOP CT could be considered as potentially treatment related.
The other two patients developed a lung carcinoma and
Table 3. Treatment approach
MZL PBL
(N = 24),
n (%)
Follicular PBL
(N = 36),
n (%)
Total,
n (%)
Surgery alone 5 (21) 6 (17) 11 (18)
CT alone 1 (4) 6 (17) 7 (12)
RT alone 5 (21) 4 (11) 9 (15)
Surgery and CT 2 (8) 4 (11) 6 (10)
Surgery and RT 8 (34) 7 (19) 15 (25)
Surgery + CT + RT 2 (8) 6 (17) 8 (13)
CT + RT 1 (4) 3 (8) 4 (7)
Surgery (alone or not) 17 (71) 23 (64) 40 (67)
CT (alone or not)a 6 (25) 19 (53) 25 (42)
RT (alone or not) 16 (67) 20 (56) 36 (52)
aP = 0.03, Pearson’s chi-square test.
MZL, marginal-zone lymphoma; PBL, primary breast lymphoma; CT,
chemotherapy; RT, radiotherapy.
Table 4. Disease progression or death during follow-up according to
stage and surgery
MZL PBL
(N = 24),
n (%)
P (log
rank)a
Follicular PBL
(N = 36),
n (%)
P (log
rank)a
Total events 10 (41.7) 19 (52.8)
Surgery
Alone 1/5 (20.0) 0.16 4/6 (66.7) 0.50
With adjuvant therapy 6/12 (50.0) 8/17 (47.1)
Surgery not performed 3/7 (42.8) 7/13 (53.8)
Ann Arbor stage IE 9/17 (52.9) 12/26 (46.1)
Surgery
Alone 1/3 (33.3) 0.37 4/5 (80.0) 0.07
With adjuvant therapy 5/10 (50.0) 5/14 (35.7)
Surgery not performed 3/4 (75.0) 3/7 (42.8)
Ann Arbor stage IIE + IV 1/7 (14.3) 7/10 (70)
Surgery
Alone 0/2 (–) 0/1 (–)
With adjuvant therapy 1/2 (50.0) 3/3 (100)
Surgery not performed 0/3 (–) 4/6 (66.7)
aComparing surgery versus surgery + adjuvant therapy.
MZL, marginal-zone lymphoma; PBL, primary breast lymphoma.
Figure 1. Fifteen-year progression-free survival in follicular and marginal-
zone primary breast lymphomas.
Figure 2. Fifteen-year overall survival in follicular and marginal-zone
primary breast lymphomas.
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a cholangiocarcinoma: these patients were treated for PBL with
surgery alone and a combination of surgery and breast RT,
respectively.
discussion
We present the results of the largest study ever conducted on
histologically low-grade PBL. We collected information on
many aspects of this disease, including clinical characteristics,
treatment and outcomes. Despite the large number of patients,
this study still has some weaknesses typical of multicentric
retrospective analysis, including different national regulations
concerning shipment of histological specimens, which
prevented the performance of central histology review.
As shown by a large investigation recently published by
IELSG [23], DLBCL is the most frequent histology among
patients with PBL. Low-grade histological subtypes are
a minority, comprising 14% for follicular lymphomas and 9%
for MZL. This is a lower proportion than suggested by prior
literature on PBL [6–13] and considering the more frequent
presentation of MZL as primary extranodal lymphomas.
Clinical characteristics were similar in the two histological
groups, except that patients with follicular PBL had a lower
median age than those with MZL lymphoma (62 versus
68 years, respectively), and the median lesion diameter was
smaller in follicular lymphoma than in MZL (2.0 versus 2.8 cm,
respectively), but these differences were not statistically
significant. Bilateral synchronous PBL was uncommon,
Table 5. Summary table of time-to-event analyses
Analysis MZL PBL (N = 24) Follicular PBL (N = 36)
PFS OS PFS OS
Event-free rates (95% CI)
3 Years 72% (53% to 91%) 100% (–) 63% (47% to 80%) 75% (61% to 90%)
5 Years 56% (31% to 81%) 92% (78% to 100%) 49% (31% to 67%) 64% (47% to 81%)
10 Years 34% (5% to 62%) 65% (30% to 99%) 28% (7% to 48%) 24% (0% to 59%)
Univariate analysisa
Number of events 10 3 19 14
Treatment yearsb
HR (95% CI) 0.9 (0.2 to 3.9) d 0.9 (0.3 to 2.6) 0.9 (0.3 to 3.0)
P 0.85 0.89 0.83
IPIb
HR per unit increase (95% CI) 4.0 (0.8 to 21.0) 0.4 (0.1 to 5.0) 4.0 (1.1 to 14.4) 5.0 (0.6 to 43.1)
P 0.10 0.52 0.03 0.14
Chemotherapy given
HR (95% CI) 1.3 (0.3 to 5.2) d 1.3 (0.5 to 3.3) 0.9 (0.3 to 2.7)
P 0.67 0.60 0.83
Radiotherapy given
HR (95% CI) 4.6 (0.9 to 23.3) 1.5 (0.1 to 16.8) 0.7 (0.3 to 1.7) 0.5 (0.2 to 1.6)
P 0.07 0.74 0.41 0.27
Radical mastectomy carried out
HR (95% CI) 1.0 (0.2 to 4.7) 4.1 (0.2 to 67.0) 0.5 (0.1 to 2.3) 0.9 (0.2 to 4.2)
P 0.96 0.33 0.40 0.92
Primary tumour sizec
HR (95% CI) 1.2 (0.3 to 4.9) 5.8 (0.5 to 65.8) 1.5 (0.5 to 4.4) 1.3 (0.4 to 4.5)
P 0.77 0.16 0.40 0.65
Ann Arbor stage > IE
HR (95% CI) 0.3 (0.1 to 2.3) 1.4 (0.1 to 16.5) 1.5 (0.6 to 3.9) 0.7 (0.2 to 2.4)
P 0.24 0.79 0.38 0.53
ECOG > 1
HR (95% CI) 3.2 (1.1 to 9.5) 2.4 (0.5 to 11.6) 2.3 (1.2 to 4.5) 2.7 (1.4 to 5.3)
P 0.04 0.29 0.01 0.003
Age > 60 years
HR (95% CI) 0.3 (0.1 to 1.3) 0.4 (0.1 to 5.1) 3.3 (1.2 to 9.3) 7.1 (1.6 to 31.9)
P 0.10 0.52 0.02 0.01
aAny hazard ratio and pertinent P value derive form unadjusted univariate analysis.
bTreatment years categories: £1995 versus >1995.
cPrimary tumour size categories: £5 versus >5 cm.
dNot estimable due to lack of events within the reference category.
MZL, marginal-zone lymphoma; PBL, primary breast lymphoma; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence
interval.
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occurring in only 5% of patients, less than previously reported
in literature [24]. Our data showed a similar sensitivity of
radiological imaging, such as mammography or ultrasound, as
reported in literature [24].
Being a retrospective study, there was a large variability in the
treatment. Surgery, RT and CT were used alone or in
combination, leading to a 98% of ORR with a 93% of CR.
About two-thirds of the patients underwent further surgery
after the diagnostic procedure; this wide use of surgery may be
explained with the need to confirm the diagnosis of PBL after
FNA cytology and the insensitivity of radiological imaging in
obtaining a histological definition, not only among NHL
subtypes but also with breast cancer. However, a total
mastectomy was carried out in only nine cases, and the
majority of patients underwent less extensive surgery such as
lumpectomy or quadrantectomy. We did not observe any
advantage in terms of PFS and OS in those patients who
underwent mastectomy, shown in a large study conducted on
both low- and high-grade PBL [25]. We also observed a higher
risk of relapse in those patients who were treated with surgery
only.
The majority of patients received RT as part of the initial
treatment, which was usually delivered after surgery or biopsy.
The majority of the relapses occurred in distant sites, with only
21% of the recurrences arising in the primary disease sites
(13%) or in the contralateral breast (8%).
Because of the relatively small number of patients and the
many possible combinations, it is impossible to evaluate the
independent contribution of CT. The majority of patients who
received CT had follicular PBL. This is an atypical treatment
strategy for localised follicular NHL, considering that they were
mostly in stage I and were already treated with surgery or RT or
both, although there are some data supporting such
a combined chemoradiation approach in limited stage nodal
follicular NHL [26]. In patients with follicular PBL, the
addition of CT to surgery seemed to reduce the relapse rate,
although not statistically significant, probably because of the
small sample size. The retrospective nature of this study could
not resolve the question of whether a systemic treatment
provided additional benefit after surgery. Indeed, our data seem
to indicate a possible benefit in those patients with follicular
PBL who received an adjuvant treatment. However, the real
utility of CT following definitive local therapy with RT in early-
stage follicular lymphoma and marginal-zone NHL remains
unproven.
No patients who received RT presented a relapse within the
irradiated fields, confirming the role of this modality
treatment to prevent local recurrence. Based on that, we
recommend the use of RT to the involved sites to prevent
locoregional recurrence. Concerning the possible role of RT to
the contralateral breast to reduce the risk of relapse, we do
not recommend its routine use because of the relative
low incidence of relapse observed in the contralateral breast
(8%).
As may have been expected, OS and PFS were better in
marginal-zone PBL than in follicular PBL, although the
differences were not statistically significant. In particular,
10-year OS and PFS for follicular PBL were, respectively, 47%
and 28%, lower than observed in limited-stage nodal follicular
lymphomas, that are characterised by a far better prognosis,
even after a ‘watch-and-wait’ approach [27], suggesting that
breast localisation of follicular NHL may be an adverse
prognostic factor. The longer CSS observed in follicular PBL
could be related to the advanced age of the patients and the
associated risks of unrelated deaths.
Different clinical behaviour of lymphomas originating in
different sites is accepted, even where histological appearances
are similar, such as cutaneous and central nervous system
DLBCL compared with the nodal counterpart. Patients with
marginal-zone PBL have a similar outcome compared with
patients with other primary extranodal MZL, such as gastric
MZL after eradication therapy. Similarly, up to 50% of relapses
occur within the first 5 years of follow-up; however, most
relapses are again responsive to treatments, not immediately
affecting OS.
In our study, no patients received immunotherapy with
rituximab as part of their treatment. We could reasonably
hypothesise that rituximab could be effective and could
improve the outcome in these CD20-positive lymphomas, as
already demonstrated in nodal follicular lymphomas [28] and
in extranodal MZL [29].
acknowledgements
The following collaborators also contributed cases to this study:
S. Crabb, Royal South Hants Hospital, The Wessex Medical
Oncology Unit, Southampton, UK; V. Ballova, National Cancer
Institute, Bratislava, Slovakia; L. Devizzi, National Cancer
Institute of Milan, Milan, Italy; M. Federico, Policlinico
Cattedra di Oncologia Medica Oncology Department,
University of Modena, Modena, Italy; H. Gomez Moreno,
Instituto de Enfermedadas Neoplasicas, Lima, Peru; J. Vose and
M. Bast, Department of Internal Medicine, University of
Nebraska Medical Centre Omaha, Omaha, NE, USA; A. Grigg,
Royal Melbourne Hospital, Melbourne, Australia; A. Lennard,
Department of Haematology, Royal Victoria Infirmary,
Newcastle-Upon-Tyne, UK; I. Poddubnaja, Cancer Research
Centre of RAMS, NN Blokhin Cancer Research Center, Russian
Academy of Medical Sciences, Moscow, Russia; M. Musso,
Department of Haematoncology and Bone Marrow Transplant,
Hospital ‘‘La Maddalena’’, Palermo, Italy; G. Pinotti, Unita`
Operativa di Oncologia Medica, Ospedale di Circolo
Figure 3. Fifteen-year cause-specific survival in follicular and marginal-
zone primary breast lymphomas.
original article Annals of Oncology
1998 | Martinelli et al. Volume 20 | No. 12 | December 2009
Fondazione Macchi, Varese, Italy; D. Christie, East Coast
Cancer Center, Tugun, Australia.
references
1. Ha CS, Dubey P, Goyal LK et al. Localized primary non-Hodgkin’s lymphoma of
the breast. Am J Clin Oncol 1998; 21: 376–380.
2. Giardini R, Piccolo C, Rilke F. Primary non-Hodgkin’s lymphoma of the female
breast. Cancer 1992; 69: 725–735.
3. Bobrow LG, Richards MA, Happerfield LC et al. Breast lymphomas:
a clinicopathologic review. Hum Pathol 1993; 24: 274–278.
4. Zucca E, Conconi A, Pedrinis E et al. Nongastric marginal zone B-cell lymphoma
of mucosa-associated lymphoid tissue. Blood 2003; 101: 2489–2495.
5. Rossi D, Berra E, Marino M et al. Histogenesis and pathogenesis of primary
breast lymphoma. Blood 2004; 104: (Abstr. 1371).
6. DeBlasio D, McCormick B, Straus D et al. Definitive irradiation for localized non-
Hodgkin’s lymphoma of breast. Int J Radiat Oncol Biol Phys 1989; 17: 843–846.
7. Au WY, Chan AC, Chow LW, Liang R. Lymphoma of the breast in Hong Kong
Chinese. Hematol Oncol 1997; 15: 33–38.
8. Domchek SM, Hecht JL, Fleming MD et al. Lymphomas of the breast: primary
and secondary involvement. Cancer 2002; 94: 6–13.
9. Wong WW, Schild SE, Halyard MY, Schomberg PJ. Primary non-Hodgkin
lymphoma of the breast: the Mayo clinic experience. J Surg Oncol 2002; 80:
19–25.
10. Aviles A, Delgado S, Nambo MJ et al. Primary breast lymphoma: results of
a controlled clinical trial. Oncology 2005; 69: 256–260.
11. Ryan GF, Roos DR, Seymour JF. Primary non-Hodgkin’s lymphoma of the breast:
retrospective analysis of prognosis and patterns of failure in two Australian
centers. Clin Lymphoma Myeloma 2006; 6: 337–341.
12. Choo SP, Lim ST, Wong EH, Tao M. Breast lymphoma: favorable prognosis after
treatment with standard combination chemotherapy. Onkologie 2006; 29:
14–18.
13. Ganjoo K, Advani R, Mariappan MR et al. Non-Hodgkin’s lymphoma of the
breast. Cancer 2007; 110: 25–30.
14. Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas
derived from marginal zone B cells: a model of antigen-driven
lymphoproliferation. Blood 2006; 107: 3034–3044.
15. Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin’s
disease staging classification. Cancer Res 1971; 31: 1860–1861.
16. Shipp MA, Harrington DP, Anderson JR et al. The International Non-Hodgkin’s
Lymphoma Prognostic Factors Project. A predictive model for aggressive non-
Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987–994.
17. Solal-Ce´ligny P, Roy P, Colombat P et al. Follicular lymphoma international
prognostic index. Blood 2004; 104: 1258–1265.
18. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment.
Cancer 1981; 47: 207–214.
19. Jaffe E, Harris NL, Stein H et al. World Health Organization Classification of
Tumours: Pathology and Genetics of Tumours of the Haematopoietic and
Lymphoid Tissues. Lyon, France: IARC Press 2001.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.
J Am Stat Assoc 1958; 53: 457–481.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in
its consideration. Cancer Chemother Rep 1966; 50: 163–170.
22. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187–220.
23. Ryan G, Martinelli G, Kuper-Hommel M et al. Primary diffuse large B-cell
lymphoma of the breast: prognostic factors and outcomes of a study by the
International Extranodal Lymphoma Study Group. Ann Oncol 2008; 19:
233–241.
24. Yang WT, Lane DL, Le-Petross HT et al. Breast lymphoma: imaging findings of
32 tumors in 27 patients. Radiology 2007; 245: 692–702.
25. Jennings WC, Baker RS, Murray SS et al. Primary breast lymphoma. The role of
mastectomy and the importance of lymph node status. Ann Surg 2007; 245:
784–789.
26. Seymour JF, Pro B, Fuller LM et al. Long-term follow up of a prospective study of
combined modality therapy for stage I-I indolent non-Hodgkin’s lymphoma. J Clin
Oncol 2003; 21: 2115–2122.
27. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s
lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22:
1454–1459.
28. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared
with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;
105: 1417–1423.
29. Conconi A, Martinelli G, Thie´blemont C et al. Clinical activity of rituximab in
extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102:
2741–2745.
Annals of Oncology original article
Volume 20 | No. 12 | December 2009 doi:10.1093/annonc/mdp238 | 1999
